OEP’s growth strategy is focused on four main lines of business.
OEP has been the commercial partner of choice for global pharmaceutical companies for nearly 40 years.
OEP partners with commercial distributors to manufacture and market products in the U.S. and other select markets.
Partners rely on our financial means, technology, and manufacturing capacity to co-develop and launch 505(b)(2)s.
Our state-of-the art facilities are TAA-compliant and USFDA-certified. We offer efficient and high-quality Clinical Trial Operation (CTO) services.
With nearly 40 years of local regulatory and sales expertise, and 350+person sales teams in 7 countries, OEP delivers top sales results in our countries of operation.
Over the last 10 years, OEP has developed a growing generics portfolio. We partner with commercial distributors to market our products in the U.S. and other select markets.
Our FDA-certified, PIC/S GMP facility produces medicines at formulations and quantities that can be tailored for each stage, from trial to commercial production. All products are made in Taiwan, a TAA-compliant country. We offer CMO/CDMO as part of a packaged suite, or as a standalone service.
Our CRO team is designed to be agile, allowing us to meet challenging clinical trial timelines and deliver truly exceptional clinical trial research services throughout Asia (including Taiwan, Singapore, and Korea), Australia, and New Zealand. Our mission is to provide efficient site selection and trial management services with high-quality and timely clinical data in a cost-effecitive manner.
© 2020 OEP Pharma. All right reserved.